Alivus Life Sciences
Alivus Life Sciences
HealthcareKey Fundamentals
SmallcapPharmaceuticalsHealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 27.4%
Weaknesses
2- The company has delivered a poor sales growth of 6.24% over past five years.
- Company has high debtors of 153 days.
Growth Rate
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 2d agoAlivus Life Sciences Ltd is a small-cap healthcare company with a market cap of ₹17,015 Cr trading at a PE of 28.3x. The company is nearly debt-free and has delivered a 5-year ROE of 21%, but revenue growth has been sluggish at a 5-year CAGR of just 6%. Profit growth has recently accelerated to 25% TTM, while high debtor days of 153 remain a concern.
- Nearly debt-free balance sheet reduces financial risk and interest burden, providing flexibility for future investments
- Consistent return on equity with a 5-year average ROE of 21% and 3-year ROE of 19%, indicating efficient capital allocation
- TTM profit growth of 25% significantly outpaces the 5-year compounded profit CAGR of 9%, suggesting margin expansion or operational improvement
- Healthy dividend payout of 27.4% with a dividend yield of 0.36%, showing commitment to returning capital to shareholders
- Stock price CAGR of 47% over the past 1 year reflects strong market re-rating and investor confidence
- 3-year stock CAGR of 31% has meaningfully outperformed the broader market, indicating sustained momentum
- Healthcare sector positioning provides defensive characteristics and exposure to India's growing domestic pharma and life sciences market
- Last year ROE of 18% remains well above cost of equity for most Indian companies, sustaining value creation
- Poor 5-year compounded sales growth of just 6%, well below healthcare sector peers, raising questions about competitive positioning
- High debtor days of 153 indicate significant working capital strain and potential collection risk from customers
- PE of 28.3x appears elevated relative to the modest 6% 5-year sales CAGR, suggesting the stock may be priced for growth it has not consistently delivered
- TTM sales growth has decelerated to 8%, only marginally above the 5-year average of 6%, indicating no structural acceleration in topline
- Price-to-book ratio of 5.13x is on the higher side for a company growing revenues in single digits
- 10-year data is unavailable for ROE, sales, and profit growth, limiting visibility into long-term track record and consistency
- 52-week high and low data are unavailable, making it difficult to assess current valuation relative to recent trading range
- 3-year compounded profit growth of only 6% suggests the recent 25% TTM profit jump may not be sustainable without corresponding revenue acceleration
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 2h ago- 76% stake in IQGEN-X Pharma Aug 18
Board approved acquisition of 76% stake in IQGEN-X Pharma for ₹9.12 crore, adding formulation development capabilities across oral solids, injectables, and ophthalmics. Deal expected to close by December 6, 2026, creating an integrated API + CDMO platform spanning North America, Europe, Japan, and India.
- ₹5 dividend approved at AGM Sep 8
All four resolutions passed at the 15th AGM with overwhelming shareholder support, including approval of a ₹5 per share dividend and director reappointment.
- Kotak Healthcare Forum attendance Sep 11
Alivus will attend the Kotak Healthcare Forum 2026 on September 17 in Mumbai for group and one-on-one investor meetings.
- Investor meetings with major funds Sep 5
One-on-one meetings scheduled with Breakout Capital, UTI, Kotak Mutual Fund, and Param Capital in Mumbai on September 9, 2026.
- Analyst engagement series planned Aug 25
Series of investor and analyst meetings announced with Mirae Asset and Emkay Global from August 28 to September 2, 2026.
TL;DR: Alivus Life Sciences is on an expansion footing, with the ₹9.12 crore IQGEN-X acquisition adding formulation and CDMO capabilities to its existing API portfolio, particularly in oncology. Shareholder confidence appears solid with all AGM resolutions passing and a ₹5 dividend declared. No material headwinds surfaced in recent news, and active engagement with institutional investors like Mirae Asset, UTI, and Kotak suggests growing market interest. The key forward risk is execution on integrating IQGEN-X and delivering on the end-to-end CDMO platform promise by the December 2026 closing deadline.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 578 | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 |
| Expenses | 385 | 428 | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 429 |
| Operating Profit | 193 | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 |
| OPM % | 33% | 28% | 30% | 26% | 27% | 27% | 30% | 31% | 29% | 30% | 34% | 31% | 33% |
| Other Income | 2 | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | -12 | 23 | 22 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 13 | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 |
| PBT | 182 | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 |
| Tax % | 26% | 25% | 26% | 24% | 26% | 25% | 26% | 26% | 25% | 25% | 24% | 25% | 25% |
| Net Profit | 135 | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 |
| EPS in Rs | 11.05 | 9.69 | 9.69 | 7.99 | 9.1 | 7.78 | 11.18 | 11.58 | 9.91 | 10.6 | 12.25 | 13.25 | 13.04 |
Profit & Loss
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 886 | 1,537 | 1,885 | 2,123 | 2,161 | 2,283 | 2,387 | 2,552 | 2,590 |
| Expenses | 0 | 638 | 1,064 | 1,294 | 1,506 | 1,518 | 1,608 | 1,702 | 1,754 | 1,754 |
| Operating Profit | 0 | 248 | 473 | 592 | 617 | 643 | 675 | 684 | 798 | 837 |
| OPM % | -4% | 28% | 31% | 31% | 29% | 30% | 30% | 29% | 31% | 32% |
| Other Income | 0 | 0 | 11 | 0 | 14 | 28 | 11 | 33 | 34 | 48 |
| Interest | 0 | 1 | 34 | 88 | 28 | 1 | 2 | 2 | 5 | 5 |
| Depreciation | 0 | 19 | 29 | 33 | 38 | 42 | 53 | 61 | 75 | 79 |
| PBT | 0 | 228 | 421 | 471 | 565 | 629 | 631 | 654 | 751 | 801 |
| Tax % | 4200% | 14% | 26% | 25% | 26% | 26% | 25% | 26% | 25% | — |
| Net Profit | 0 | 196 | 313 | 352 | 419 | 467 | 471 | 486 | 564 | 603 |
| EPS in Rs | -430 | 998 | 1,597 | 359 | 34.17 | 38.11 | 38.43 | 39.63 | 45.99 | 49.14 |
| Div. Payout % | 0% | 0% | 0% | 0% | 61% | 110% | 59% | 13% | 11% | — |
Balance Sheet
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 2 | 2 | 2 | 25 | 25 | 25 | 25 | 25 |
| Reserves | -1 | 86 | 400 | 751 | 2,030 | 2,114 | 2,308 | 2,793 | 3,308 |
| Borrowings | 0 | 0 | 0 | 0 | 3 | 19 | 17 | 57 | 57 |
| Other Liabilities | 1 | 1,387 | 1,324 | 1,244 | 414 | 545 | 501 | 537 | 594 |
| Total Liabilities | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 | 3,983 |
| Fixed Assets | 0 | 456 | 546 | 573 | 595 | 781 | 805 | 955 | 1,038 |
| CWIP | 0 | 80 | 11 | 14 | 92 | 62 | 106 | 102 | 284 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 478 | 780 |
| Other Assets | 0 | 939 | 1,169 | 1,410 | 1,784 | 1,860 | 1,939 | 1,877 | 1,881 |
| Total Assets | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 | 3,983 |
Cash Flow
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | 10 | 195 | 388 | 598 | 306 | 414 | 392 | 565 |
| Investing | 0 | -9 | -51 | -69 | -122 | -147 | -116 | -616 | -570 |
| Financing | 0 | 1 | -137 | -214 | -79 | -388 | -279 | -6 | -64 |
| Net Cash Flow | 0 | 2 | 8 | 106 | 397 | -228 | 18 | -230 | -69 |
| Free Cash Flow | 0 | 1 | 144 | 322 | 466 | 143 | 285 | 226 | 259 |
| CFO/OP | 4,800 | 14 | 61 | 84 | 119 | 71 | 85 | 81 | 93 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 44 | 185 | 152 | 120 | 116 | 136 | 122 | 148 | 153 |
| Inventory Days | 162 | 441 | 227 | 214 | 185 | 224 | 251 | 237 | 246 |
| Days Payable | 41 | 201 | 111 | 92 | 110 | 158 | 139 | 137 | 132 |
| Cash Conversion Cycle | 165 | 424 | 268 | 241 | 190 | 202 | 235 | 248 | 267 |
| Working Capital Days | -2,059 | -186 | -37 | 12 | 149 | 176 | 188 | 201 | 194 |
| ROCE % | — | 529% | 186% | 97% | 42% | 30% | 28% | 25% | 24% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Alivus Life Sciences insights
56 extracted metrics + investor summaries across FY18–FY27.
Documents
Frequently Asked Questions about Alivus Life Sciences
What does Alivus Life Sciences Ltd do?
Where is Alivus Life Sciences Ltd (ALIVUS) listed?
Which sector does Alivus Life Sciences Ltd belong to?
What is the market capitalisation of Alivus Life Sciences Ltd?
What is the PE ratio of Alivus Life Sciences Ltd?
What is the 52-week high and low of Alivus Life Sciences Ltd?
Does Alivus Life Sciences Ltd pay dividends?
What is the Return on Equity (ROE) of Alivus Life Sciences Ltd?
Company Information
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ALIVUS.md for Alivus Life Sciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.